A randomized, double-blind, placebo-controlled, phase 2, 6-month study to evaluate the safety, tolerability and exploratory efficacy of CT1812 in subjects with mild to moderate Dementia with Lewy Bodies.
|Male and Female Patients
|U.S. Govt. ID:
|Katrina Cuasay: / email@example.com
This study is of a drug called CT1812, that is being evaluated as a possible treatment for Dementia with Lewy Bodies. In this study, which is carried out at multiple sites in the country, participants receive either CT1812 at one of two doses or placebo. The duration of the study is up to about 35 weeks. Participants receive blood tests, cerebrospinal fluid testing, pen and paper tests, and an MRI scan as part of the study procedures.
Lawrence Honig, MD, PhD
|Are you between the ages of 50-85?
|Have you been diagnosed with mild to moderate Dementia with Lewy Bodies (DLB)?
|Do you have a caregiver/study partner who is able to attend all study visits and participate in some study assessments?